EMMA projects - The European Mouse Disease Clinic (EUMODIC)
A distributed phenotyping resource for studying human disease
What is EUMODIC?
EUMODIC will bring together a large consortium of 18 research institutes in 8 European countries who are experts in the field of mouse functional genomics and phenotyping.
EUMODIC will undertake a primary phenotype assessment of up to 650 mouse mutant lines. In addition, a number of these mutant lines will be subject to an in depth secondary phenotype assessment.
Mutant lines will be made available from the EUCOMM (European Conditional Mouse Mutagenesis) project which aims to produce conditional mutations in 13000 mouse genes.
In addition, a number of these mutant lines will be subject to a more in depth secondary phenotype assessment.
What are the aims of EUMODIC?
The EUMODIC consortium will build on the work in the EUMORPHIA project that delivered a comprehensive database - EMPReSS - of Standard Operating Procedures (SOPs) that can be used to determine the phenotype of a mouse.
EUMODIC has developed a selection of these screens called EMPReSSslim, which is structured for comprehensive primary, high throughput phenotyping of large numbers of mice.
Primary phenotype assessment using EMPReSSslim will be undertaken in four large-scale phenotyping centres at the Helmholtz Zentrum München, Germany; ICS, France; MRC Harwell, UK and the Sanger Institute, UK.
A wider network of centres with expertise in particular phenotyping areas will undertake more complex secondary phenotyping screens and apply them to a subset of the mice which have shown interesting phenotypes in the primary screen.
EMMA will archive and make available, to the wider biomedical research community all 330 mouse mutant lines produced by EUMODIC.